The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...
Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...
The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...
The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...
AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...
The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...
Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...
The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback